Schonfeld Strategic Advisors’s Stoke Therapeutics STOK Stock Holding History

Schonfeld Strategic Advisors’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.61M	Sell	49,302 -13,807	-22%	-$453K	0.01%	907
2025 Q4	$2M	Sell	63,109 -174,906	-73%	-$5.26M	0.01%	875
2025 Q3	$5.59M	Buy	238,015 +63,301	+36%	+$1.08M	0.03%	549
2025 Q2	$1.98M	Sell	174,714 -160,646	-48%	-$1.53M	0.01%	996
2025 Q1	$2.23M	Buy	335,360 +43,565	+15%	+$406K	0.01%	918
2024 Q4	$3.22M	Buy	+291,795	New	+$3.58M	0.02%	648
2023 Q3	–	Sell	-62,902	Closed	-$669K	–	2270
2023 Q2	$669K	Buy	+62,902	New	+$669K	0.01%	1116

Other funds holding STOK

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Schonfeld Strategic Advisors's STOK Position: Q1 2026 in Review

Schonfeld Strategic Advisors reduced its Stoke Therapeutics (STOK) stake by 22% in Q1 2026, selling an estimated $453K and leaving 49,302 shares worth $1.61M. The position accounts for 0.01% of the portfolio, ranked #907.

Schonfeld Strategic Advisors first reported a position in STOK in Q2 2023 and has held it in 7 quarters since. The position peaked at $5.59M in Q3 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

Schonfeld Strategic Advisors held 49,302 shares of Stoke Therapeutics worth $1.61M as of Q1 2026.
Schonfeld Strategic Advisors sold 13,807 Stoke Therapeutics shares in Q1 2026, an estimated $453K.
Stoke Therapeutics made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #907 holding.
Schonfeld Strategic Advisors first reported a position in Stoke Therapeutics in Q2 2023 and has held it in 7 quarters since.
Schonfeld Strategic Advisors's Stoke Therapeutics position peaked at $5.59M in Q3 2025.
196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.